What Is the Scope of U.S. Patent 5,252,341?
U.S. Patent 5,252,341 covers the chemical compound known as risperidone, a dopamine D2 receptor antagonist used primarily for treating schizophrenia, bipolar disorder, and irritability associated with autism. The patent specifically claims the chemical structure of risperidone and its pharmaceutical formulations, methods of synthesis, and therapeutic uses.
Patent Claims Breakdown
The patent claims can be summarized as follows:
-
Chemical Structure: The primary claim pertains to the compound risperidone, characterized by the chemical formula: 4-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]piperidine-1-carboxylic acid methyl ester.
-
Pharmaceutical Composition: Claims include methods for preparing pharmaceutical formulations containing risperidone, including tablets, capsules, and injectable solutions.
-
Methods of Use: Claims encompass treatment methods for schizophrenia and bipolar disorder through administration of risperidone.
-
Synthesis Methods: The patent details specific synthetic routes for producing risperidone, including intermediates and reaction conditions.
The patent was filed on June 29, 1992, and issued on April 4, 1993.
How Does the Claims Landscape Affect the Patent’s Enforceability and Commercial Use?
The claims focus on the chemical structure and its direct derivatives, with extensive coverage of the synthesis process and medical use cases. These broad claims establish the patent's initial strength but have faced challenges due to emerging generics and subsequent patents.
Validity and Challenges
-
The patent's novelty relied on the synthesis process and specific compound structure. Subsequent references have challenged its validity based on prior art, particularly earlier benzisoxazole derivatives.
-
The scope was narrowed over time by court rulings and patent office re-examinations, especially as related patents for similar compounds emerged, limiting the commercial window for exclusivity.
Patent Term and Expiry
- The patent was filed in 1992 and issued in 1993; its standard 20-year term would end in June 2012, barring extensions or patent term adjustments. Generics entered the market post-expiry, reducing the patent's enforceability.
Patent Landscape for Risperidone and Analogues
The patent landscape surrounding risperidone includes multiple patents from its original developers (e.g., Johnson & Johnson, Janssen Pharmaceuticals) and follow-on patents covering formulations, methods of administration, and derivatives.
Key Related Patents
| Patent Number |
Title |
Filing Date |
Expiration |
Notes |
| US 4,879,288 |
Risperidone synthesis |
Dec 8, 1986 |
2004 |
Broader synthesis process patent |
| US 6,117,980 |
Extended formulation patents |
Nov 27, 1998 |
2018 |
Covering controlled-release formulations |
| US 7,143,620 |
Crystal forms of risperidone |
May 27, 2004 |
2024 |
Patents on specific polymorphs |
The patent landscape indicates a strategy to extend exclusivity through secondary and improvement patents, including formulations and polymorphs, until approximately 2024.
Market Entry and Patent Expiry
Post expiry of the original patent in 2012, multiple generics entered the U.S. market. Several subsequent patents on formulations or formulations' methods expired later, enabling broader generic competition.
Key Patent Policy and Legal Dynamics
-
Patent rights on risperidone were subject to challenges under Paragraph IV certifications, leading to litigation and patent settlements, common in blockbuster drugs.
-
The Hatch-Waxman Act's mechanisms facilitated generic entry following patent expiry, which occurred in 2012 for the original patent.
-
Subsequent patents on specific formulations or delivery methods have extended patent protection until 2024, although these are narrower in scope and more vulnerable to invalidation or non-infringement defenses.
Summary
-
Scope: Encompasses risperidone's chemical structure, synthesis, formulations, and therapeutic uses.
-
Claims: Focus on the compound, manufacturing process, and medical use, with some claims on specific formulations and crystalline forms.
-
Patent Landscape: Dominated by original compound patent (expiring 2012), followed by secondary patents on formulations and polymorphs, extending potential exclusivity until approximately 2024.
-
Market Impact: Original patent provided market exclusivity in the U.S. until 2012. Post-expiry, generic competition increased markedly. Patents on formulations and polymorphs may provide some market leverage until their expiration.
Key Takeaways
-
The core patent on risperidone solidified exclusivity for the original compound until 2012, after which generics flooded the market.
-
Follow-up patents, including formulations and crystalline modifications, aim to extend commercial advantages until 2024, though challenge and invalidation are possible.
-
The legal strategy around secondary patents continues to influence market dynamics in the risperidone space.
-
Patent challenges and litigation historically impacted timing and scope of market exclusivity.
-
Companies seeking to develop risperidone-related drugs need to consider the expiration timelines and existing patent claims globally.
FAQs
1. What was the primary legal protection offered by U.S. Patent 5,252,341?
It protected the chemical structure of risperidone, methods for manufacturing it, and its therapeutic uses, providing 20 years of patent protection until 2012.
2. Are there any active patents related to risperidone today?
Most original claims expired in 2012. However, patents on formulations, polymorphs, or methods of administration related to risperidone may still be active until 2024.
3. How has patent litigation affected risperidone?
Patent litigation, including patent challenges under Paragraph IV, has delayed generic entry and influenced settlement agreements, thereby extending market exclusivity temporarily.
4. What strategies have companies used to extend patent protection for risperidone?
Filing secondary patents on extended-release formulations, specific crystalline forms, and manufacturing processes prolongs exclusivity until around 2024.
5. Can competitors develop new risperidone derivatives without infringing?
Yes, but they must avoid patent claims on core structure, synthesis methods, or specific formulations protected by active patents. Careful freedom-to-operate analysis is necessary.
Sources:
- U.S. Patent and Trademark Office, Patent No. 5,252,341 details.
- FDA Approved Drug Labels for Risperdal.
- Patent landscape analysis reports from Clarivate and IAM.
- Legal case filings related to risperidone patents.
